12,757 research outputs found
Dark Scalar Doublets and Neutrino Tribimaximal Mixing from A_4 Symmetry
In the context of A_4 symmetry, neutrino tribimaximal mixing is achieved
through the breaking of A_4 to Z_3 (Z_2) in the charged-lepton (neutrino)
sector respectively. The implied vacuum misalignment of the (1,1,1) and (1,0,0)
directions in A_4 space is a difficult technical problem, and cannot be treated
without many auxiliary fields and symmetries (and perhaps extra dimensions). It
is pointed out here that an alternative scenario exists with A_4 alone and no
redundant fields, if neutrino masses are "scotogenic", i.e. radiatively induced
by dark scalar doublets as recently proposed.Comment: 8 pages, 2 figures, 1 reference and 1 paragraph adde
Z_3 Dark Matter and Two-Loop Neutrino Mass
Dark matter is usually distinguished from ordinary matter by an odd-even
parity, i.e. the discrete symmetry Z_2. The new idea of Z_3 dark matter is
proposed with a special application to generating radiative Majorana neutrino
masses in two-loop order.Comment: expanded (9 pages, 2 figures), 2 references adde
Resistencia frente a la enfermedad: relato de un cuerpo dañado por la diabetes
Objetivo: comprender el punto de vista acerca de la enfermedad de personas con diabetes mellitus tipo 2 en moradores de una comunidad del Estado de México. Materiales y métodos: estudio con una aproximación etnográfica que sustentó el análisis de los datos. La investigación se realizó en un centro de atención primaria de salud, participaron ocho personas que asistieron al consultorio de enfermería durante el periodo comprendido entre diciembre de 2009 y julio de 2010. Se respetaron los aspectos éticos propios de la investigación. Resultados: al escuchar las voces de los pacientes que viven con diabetes lograrmos introducirnos en el mundo de la en- fermedad mediante sus relatos. Conclusiones: la aproximación etnográfica permite comprender el sentido que le dan los pacientes con diabetes mellitus tipo 2 a su enfermedad, desde las creencias y los hábitos. Tal como ellos lo relatan, con su experiencia logran resistir la persistencia de la enfermedad
Predictors of short and long term recurrence of suicidal behavior in borderline personality disorder
Objective: To evaluate the incidence of suicidal outcomes and risk factors for short- and long-term recurrence of suicidal behavior (SB) among high-risk borderline personality disorder (BPD) patients during a 24-month prospective follow-up period. Methods: A multicenter prospective cohort study was designed to compare data obtained from 136 patients admitted to the emergency department for current suicidal ideation (SI) or a recent suicide attempt (SA). Subjects were clinically evaluated and monitored for a new SA or suicide. Results: The incidence of a new SA was 25.63 events/100 persons-year, and one patient died by suicide. Child sexual abuse (CSA) was the only significant predictor throughout the complete follow-up period. The absence of prior psychiatric treatment predicts the recurrence of SB in the first 6 months of follow-up. Patient age, poor psychosocial functioning before hospitalization, age at first SA, and having multiple suicide attempts increased risk of SB recurrence at the long-term period (24th months). In addition, there was an interaction between CSA and poor psychosocial functioning that increased risk of SB. Conclusion: The risk of recurrence was higher during the first 6 months. Risk factors at 6 and 24 months vary. These findings are important for implementing suicide strategies.Fil: Rodante, Demián E.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacologia; ArgentinaFil: Grendas, Leandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacologia; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital Municipal "José Tiburcio Borda"; ArgentinaFil: Puppo, Soledad. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacologia; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Vidjen, Patricia. Gobierno de la Ciudad de Buenos Aires. Hospital Municipal "José Tiburcio Borda"; ArgentinaFil: Portela, Alicia. Gobierno de la Ciudad de Buenos Aires. Hospital Municipal "José Tiburcio Borda"; ArgentinaFil: Rojas, Sasha M.. University of Arkansas for Medical Sciences; Estados UnidosFil: Chiapella, Luciana Carla. Universidad Nacional de Rosario. Facultad de Cs.bioquímicas y Farmaceuticas. Departamento de Cs.fisiologicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Daray, Federico Manuel. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacologia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentin
Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program
Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program
© 2015, Springer International Publishing Switzerland. Background: The concept of pharmaceutical care is operationalized through pharmaceutical professional services, which are patient-oriented to optimize their pharmacotherapy and to improve clinical outcomes. Objective: The objective of this study was to estimate the incremental cost-effectiveness ratio (ICER) of a medication review with follow-up (MRF) service for older adults with polypharmacy in Spanish community pharmacies against the alternative of having their medication dispensed normally. Methods: The study was designed as a cluster randomized controlled trial, and was carried out over a time horizon of 6 months. The target population was older adults with polypharmacy, defined as individuals taking five or more medicines per day. The study was conducted in 178 community pharmacies in Spain. Cost-utility analysis adopted a health service perspective. Costs were in euros at 2014 prices and the effectiveness of the intervention was estimated as quality-adjusted life-years (QALYs). In order to analyze the uncertainty of ICER results, we performed a non-parametric bootstrapping with 5000 replications. Results: A total of 1403 older adults, aged between 65 and 94 years, were enrolled in the study: 688 in the intervention group (IG) and 715 in the control group (CG). By the end of the follow-up, both groups had reduced the mean number of prescribed medications they took, although this reduction was greater in the IG (0.28 ± 1.25 drugs; p < 0.001) than in the CG (0.07 ± 0.95 drugs; p = 0.063). Older adults in the IG saw their quality of life improved by 0.0528 ± 0.20 (p < 0.001). In contrast, the CG experienced a slight reduction in their quality of life: 0.0022 ± 0.24 (p = 0.815). The mean total cost was €977.57 ± 1455.88 for the IG and €1173.44 ± 3671.65 for the CG. In order to estimate the ICER, we used the costs adjusted for baseline medications and QALYs adjusted for baseline utility score, resulting in a mean incremental total cost of −€250.51 ± 148.61 (95 % CI −541.79 to 40.76) and a mean incremental QALY of 0.0156 ± 0.004 (95 % CI 0.008–0.023). Regarding the results from the cost-utility analysis, the MRF service emerged as the dominant strategy. Conclusion: The MRF service is an effective intervention for optimizing prescribed medication and improving quality of life in older adults with polypharmacy in community pharmacies. The results from the cost-utility analysis suggest that the MRF service is cost effective
Association of VAV2 and VAV3 polymorphisms with cardiovascular risk factors
Hypertension, diabetes and obesity are cardiovascular risk factors closely associated to the development of renal and cardiovascular target organ damage. VAV2 and VAV3, members of the VAV family proto-oncogenes, are guanosine nucleotide exchange factors for the Rho and Rac GTPase family, which is related with cardiovascular homeostasis. We have analyzed the relationship between the presence of VAV2 rs602990 and VAV3 rs7528153 polymorphisms with cardiovascular risk factors and target organ damage (heart, vessels and kidney) in 411 subjects. Our results show that being carrier of the T allele in VAV2 rs602990 polymorphism is associated with an increased risk of obesity, reduced levels of ankle-brachial index and diastolic blood pressure and reduced retinal artery caliber. In addition, being carrier of T allele is associated with increased risk of target organ damage in males. On the other hand, being carrier of the T allele in VAV3 rs7528153 polymorphism is associated with a decreased susceptibility of developing a pathologic state composed by the presence of hypertension, diabetes, obesity or cardiovascular damage, and with an increased risk of developing altered basal glycaemia. This is the first report showing an association between VAV2 and VAV3 polymorphisms with cardiovascular risk factors and target organ damage
Human Papillomavirus (HPV), minireview and collateral expected benefits of the vaccine.
Cervical neoplasia is the second leading cause of neoplastic death in Latin America. It is generally accepted that all cervical carcinomas have at least one high risk Human Papillomavirus (HPV). Due to the causal relationship of specific HPV types and cervical cancer and its role as precursor of skin lesions it is important to identify the involved genotype. HPV, as other tumor-viruses, induces oncogenesis by manipulating an array of different cellular pathways, which leads to immortalization and proliferation of the infected cells by disrupting the mitotic checkpoint upon infection of the host cell. Actually the role of the immune response in the development of cervical cancer is unknown as is the relationship between the type and level of expression of messenger RNA (mRNA) of interferon gamma (IFN-γ), transforming growth factor beta 1 (TGF-β1) and interleukin (IL)-4 in the cervical microenvironment within each of the stages of carcinogenesis with the HPV genotype causing the infection. An average annual cost to treat cervical cancer is U.S. 33,795.4 million to treat all women. Universal vaccination against HPV might result in extended benefits as the decrease in mouth and oropharynx cancers as well as the reduction in health cost for the attendance of several neoplasias
- …